TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 5763957
Drug: Proprietary cough
Normalized name: Pediaclear Cough
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary cough linctus containing 50 mg of phenylpropanolamine (in a subject taking tranylcypromine)
Study: 5763957
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of phentolamine
Study: 30107789
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Motion Simulation and Whole Body Vibration (MSim + WBV)
Study: 26867199
Drug: Gluten intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten intake (5.6 g/day) for 7 days after a 3-week gluten-free diet (GFD)
Study: 25711318
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment at a CD4 cell count of 500 cells/μL or higher
Study: 25711318
Drug: Deferring treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferring treatment until the CD4 cell count decreases to 350 cells/μL or until AIDS develops
Study: 23809257
Drug: Hybrid model
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid model of combined modified constraint induced movement therapy (mCIMT) followed by intensive bimanual training (COMBiT)
Study: 23809257
Drug: Distributed model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distributed model of standard occupational therapy and physiotherapy care (SC)
Study: 17079587
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (3 one-on-one sessions per week for 8 weeks, followed by a home program for another 6 weeks)
Study: 15514272
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d iron supplementation for 12 months
Study: 9919895
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg daily for 1 week
Study: 2965462
Drug: 2 microgram
Normalized name: Paricalcitol 2 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 microgram doses of hepatitis B vaccine (HB-Vax) administered intradermally at months 0 and 1, followed by two booster injections at months 5 and 10
Study: 2965462
Drug: 2 microgram
Normalized name: Paricalcitol 2 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 microgram doses of hepatitis B vaccine (HB-Vax) administered intradermally
Study: 29249166
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg b.i.d.
Study: 23666451
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of naloxone 0.1 mg, droperidol 2 mg, and dexamethasone 8 mg (Cm group)
Study: 23666451
Drug: Naloxone 0.1
Normalized name: naloxone 0.18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.1 mg (Nx group)
Study: 23666451
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg (Dx group)
Study: 23666451
Drug: Droperidol 1
Normalized name: droperidol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1 mg (Dr group)
Study: 19468216
Drug: Factor Seven
Normalized name: factor VIIa Injection [Sevenfact]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factor Seven for Acute Hemorrhagic Stroke (treatment group)
Study: 16624768
Drug: Mechanical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical periodontal treatment combined with tetracycline
Study: 16624768
Drug: Exclusive mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exclusive mechanical periodontal treatment
Study: 15470169
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose sufentanil (0.025 microg x kg(‐1) for the first patient and 0.1 microg x kg(‐1) for the other two patients)
Study: 15470169
Drug: Atropine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.6 mg i.v.
Study: 7862546
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of relaxation and music
Study: 8067145
Drug: Two tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets containing 100,000 binding units (BU) of the toxoid and 2,500 units of O-antigen for children 11-14 years
Study: 8067145
Drug: Four tablets
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four tablets containing 200,000 BU of the toxoid and 5,000 units of O-antigen for adolescents aged 15-17 years
Study: 2099071
Drug: Oral cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholera vaccine
Study: 28351962
Drug: β-blocker-treated Gly49
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blocker-treated Gly49 carriers
Study: 28351962
Drug: Non-carriers and
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-carriers and non-β-blocker-treated individuals
Study: 26755209
Drug: Clown therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clown therapy (interaction with clowns)
Study: 25079090
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose nevirapine during first ANC appointment
Study: 17564955
Drug: 20 U
Normalized name: vitamin E 20 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 U of oxytocin in 30 mL of saline
Study: 17564955
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of saline
Study: 15097300
Drug: ART +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART + IL-2 (1 million IU subcutaneously once daily)
Study: 9665682
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low calorie diet with 3.0 g fat/d
Study: 9665682
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low calorie diet with 12.2 g fat/d
Study: 10893703
Drug: Pethidine 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 0.7 mg/kg
Study: 30395147
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (Control)
Study: 19194119
Drug: Granisetron 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 0.5 mg per oral (days 2 and 3)
Study: 19194119
Drug: Placebo on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo on day 2 and granisetron 0.5 mg on days 3 and 4
Study: 29878583
Drug: BAY 1142524
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1142524 (1-200 mg single oral doses, 5-50 mg twice daily, 100 mg once daily for 5 days)
Study: 29878583
Drug: BAY 1142524
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1142524 (5 mg dose)
Study: 29878583
Drug: BAY 1142524
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1142524 (liquid service formulation or IR tablets)
Study: 29878583
Drug: BAY 1142524
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1142524 (multiple dosing)
Study: 16124370
Drug: Fenspiride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenspiride (2 ml/kg/day in three divided doses)
Study: 16124370
Drug: Amoxicillin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (80 mg/kg/day in three partite doses) + Oxymethazolin (0.05% nasal drops 3 x day)
Study: 12160337
Drug: Muscle Learning
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle Learning Therapy (MLT)
Study: 10352334
Drug: Desferrioxamine (DFO)
Normalized name: DFO
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desferrioxamine (DFO) 30-40 mg/kg by slow intravenous infusion
Study: 31088195
Drug: Single‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single‐ and multiple‐dose injectable Ginkgolide B (GB)
Study: 31088195
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg once‐daily dosing of Ginkgolide B (GB)
Study: 31088195
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Ginkgolide B (GB)
Study: 31088195
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Ginkgolide B (GB)
Study: 31088195
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Ginkgolide B (GB)
Study: 31088195
Drug: Repeated once‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated once‐daily dosing of Ginkgolide B (GB)
Study: 31088195
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of Ginkgolide B (GB)
Study: 25661338
Drug: Antimony treatment
Normalized name: antimony
DrugBank: Antimony (DB13110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimony treatment
Study: 23945574
Drug: Injectable penicillin‐gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable penicillin‐gentamicin combination
Study: 16782974
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg and 6 mg (given 10 min before sedation)
Study: 15255454
Drug: Multivitamin/mineral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin/mineral supplementation (36 mg vitamin E, 150 mg vitamin C, 9 mg beta-carotene) for 6 months
Study: 15255454
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule for 6 months
Study: 11296164
Drug: Montelukast and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast and Salmeterol (after 2 weeks of treatment)
Study: 9311490
Drug: Aerosolized lipid-extracted
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized lipid-extracted bovine surfactant (Alveofact) 120 mg
Study: 2878745
Drug: Intranasal synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal synthetic LHRH
Study: 28111428
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day) plus Afatinib (40 mg/day)
Study: 8884896
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin C 1 g daily
Study: 1414398
Drug: s-adenosyl-l-methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: s-adenosyl-l-methionine (SAMe)
Study: 1414398
Drug: TSH response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TSH response outside the normal range (7-25 uU/ml)
Study: 1414398
Drug: absolute deviations
Normalized name: Honey Absolute
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: absolute deviations from the mean TSH response (16 uU/ml)
Study: 16569544
Drug: Clinic-only (CO)
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic-only (CO) carvedilol titration
Study: 11685160
Drug: Noetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noetic therapy (stress relaxation, imagery, touch therapy, prayer)
Study: 11685160
Drug: Noetic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noetic therapies
Study: 9450158
Drug: pivagabine (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivagabine (1800 mg orally for 30 days)
Study: 3376901
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (400 micrograms.kg‐1.d‐1 of intravenous Zn)
Study: 24404797
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (OC)
Study: 22951317
Drug: Citicoline 1000mg
Normalized name: citicoline 1000 MG
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline 1000mg (test preparation)
Study: 22951317
Drug: Citicoline 1000mg
Normalized name: citicoline 1000 MG
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline 1000mg (reference control release tablet)
Study: 18039433
Drug: Oxycodone (prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (prolonged-release form)
Study: 16462818
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg Orlistat three times a day
Study: 10735889
Drug: Adjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant endocrine treatment (n = 250)
Study: 10735889
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (n = 112)
Study: 15251156
Drug: Adjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant endocrine treatment
Study: 10735889
Drug: Nodal status,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nodal status, estrogen receptor (ER) status, tumor size
Study: 8774551
Drug: 6 methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 methylprednisolone (6MP) i.v. for 3 days at 5 mg/kg/d and for an additional 3 days at 2.5 mg/kg/d followed by po prednisone (1 mg/kg/d)
Study: 8774551
Drug: po prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: po prednisone (1 mg/kg/d)
Study: 1635824
Drug: Inspiratory flow-resistive
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory flow-resistive load training (75 cm H2O.L-1.s in week 1 and 90 cm H2O.L-1.s in week 2)
Study: 6708393
Drug: Digitalis and
Normalized name: Digitalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitalis and diuretics (group III)
Study: 6708393
Drug: Digitalis and
Normalized name: Digitalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitalis and K+-saving diuretics (group IV)
Study: 6708393
Drug: Digitalis and
Normalized name: Digitalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitalis and K+-losing diuretics (group V)
Study: 29419917
Drug: Placebo/Metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/Metformin
Study: 25012934
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every 8 weeks after 5 initial monthly doses (2q8)
Study: 22528165
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg (Group AA)
Study: 22528165
Drug: Atorvastatin on
Normalized name: Atorvastatin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin on the day of surgery and for seven days post surgery (Group PA)
Study: 18482525
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (intravenous insulin with target glycemia levels of 80-110 mg/dl)
Study: 18482525
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy (subcutaneous insulin only when glycemia was 160 mg/dl)
Study: 18482525
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test after 4 weeks
Study: 15683372
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg) followed by misoprostol (0.8 mg)
Study: 12789384
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg initially, increased to 100 mg or decreased to 25 mg depending on efficacy and tolerance)
Study: 1810359
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg for 1 week, then 300 mg)
Study: 1810359
Drug: Mianserin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (60 mg for 1 week, then 180 mg)
Study: 1090417
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate ointment
Study: 9118626
Drug: Ointment base
Normalized name: Ointment base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment base (control)
Study: 31740368
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg twice daily for 3 months
Study: 26807956
Drug: Animal-assisted activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-assisted activities (AAA) with a dog, 30-min sessions twice weekly for 12 weeks
Study: 27155968
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with treatment as usual
Study: 25108482
Drug: Avoidance combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoidance combined with cognitive behavior therapy (Avoid + CBT)
Study: 19838130
Drug: vicriviroc (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: vicriviroc (5, 10, or 15 mg/day)
Study: 16284465
Drug: Dextrin sulphate
Normalized name: Dextrin sulphate
DrugBank: Dextrin 2-sulfate (DB06496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrin sulphate (DS) gel twice daily
Study: 16284465
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel twice daily
Study: 16284465
Drug: Dextrin sulphate
Normalized name: Dextrin sulphate
DrugBank: Dextrin 2-sulfate (DB06496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrin sulphate (DS) gel pre-sex
Study: 16284465
Drug: Dextrin sulphate
Normalized name: Dextrin sulphate
DrugBank: Dextrin 2-sulfate (DB06496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrin sulphate (DS) gel
Study: 12365857
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg orally twice daily (n=19)
Study: 12365857
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg orally thrice daily (n=20)
Study: 9798811
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education and inhaled steroids usage
Study: 7806712
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for depression over 12 weeks
Study: 2791812
Drug: Intravenous cisapride
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisapride (8.0 mg)
Study: 2791812
Drug: Oral cisapride
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cisapride (10.0 mg)
Study: 2791812
Drug: Oral cisapride
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cisapride (5.0 mg)
Study: 2791812
Drug: Intravenous cisapride
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisapride followed by intravenous atropine
Study: 1130311
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 supplementation (0.8, 2.0, or 20.0 mg of pyridoxine hydrochloride)
Study: 28376149
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin therapy (conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg)
Study: 12952833
Drug: Low-dose paclitaxel
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose paclitaxel (1.28 microg/mm2)
Study: 12952833
Drug: High-dose paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose paclitaxel (3.10 microg/mm2)
Study: 8643884
Drug: Randomized treatment
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized treatment (734 patients, 35% of total)
Study: 8643884
Drug: Non-randomized treatment
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-randomized treatment (1350 patients, 65% of total)
Study: 3908262
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg mane
Study: 22767005
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol (1 L the night before and 1 L on the day of the exam) with bisacodyl 10 mg
Study: 22767005
Drug: Mannitol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol (1 L of a 10% mannitol solution on the day of the exam) with bisacodyl 20 mg
Study: 20666948
Drug: Estrogen +
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen + progestin therapy (HT)
Study: 16181878
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose AF0144 (1.8 g/kg)
Study: 16181878
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose AF0144 (2.7 g/kg)
Study: 7774741
Drug: Syntometrine 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syntometrine 1 ml (oxytocin 5 units + ergometrine 0.5 mg)
Study: 2191071
Drug: Nopharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nopharmacological treatment group
Study: 31066315
Drug: Traditional mirror
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional mirror therapy (4 weeks)
Study: 31066315
Drug: Self-delivered mirror
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-delivered mirror therapy (6 weeks)
Study: 26285020
Drug: Caffeine-containing supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-containing supplement (CAF)
Study: 24343092
Drug: ARV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARV therapy longer than 2 years
Study: 17240224
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg orally, 4 x daily for 3 days)
Study: 17240224
Drug: Acetaminophen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1000 mg orally, 4 x daily for 3 days)
Study: 7957450
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of theophylline